Table 2.

Primary and secondary outcomes

OutcomeParicalcitol Group (n=53)Calcitriol Group (n=54)P Value
Primary outcome
 Confirmed cCa>10.5 mg/dl3 (5.7)1 (1.9)0.36
Secondary outcomes
 Any cCa>10.5 mg/dl7 (13.2)4 (7.4)0.36
 >40% PTH reduction52 (98)47 (87)0.03
 >60% PTH reduction45 (83)28 (52)<0.001
 Change in PTH, 24 wk (%)a−52±23−46±210.17
 Total capsules240 (180, 298)292 (231, 405)0.01
 Change in cCa (mg/dl)a+0.38 (0.10, 0.60)+0.28 (0.14, 0.52)0.27
 Change in phosphorus (mg/dl)a+0.2 (−0.1, 0.7)+0.3 (0.0, 0.6)0.88
 Change in alkaline phosphatase (U/L)a−9.0 (−22.2, 1.0)−13.0 (−23.5, −8.0)0.32
 Any phosphorus>4.5 mg/dl21 (40)28 (52)0.21
 eGFR (ml/min per 1.73 m2), 24 wka24.0±8.622.6±9.60.45
 Urine phosphorus/creatinine ratio (mg/g), 24 wk377 (292, 528)414 (326, 514)0.62
  • Data are expressed as the mean±SD, n (%), or median (interquartile range).

  • a These results are significantly different from baseline. See Results and Discussion sections for further details.